Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Pill Appearance Key to Patient Compliance

By BiotechDaily International staff writers
Posted on 31 Jul 2014
Heart attack patients are 30% more likely to discontinue generic cardiovascular medications if their pills change in color or shape, according to a new study.

Researchers at Brigham and Women's Hospital (Boston, MA, USA) conducted cohort and nested case–control studies to determine whether nonpersistent use of generic drugs among 11,513 patients with cardiovascular disease (CVD) after myocardial infarction (MI) is associated with inconsistent appearance of their medications. Study patients were those who discontinued their index medication for at least one month, while control patients continued treatment uninterrupted. Rates of changes in pill color and shape during the year after MI were calculated, and the odds of discordance among case and control patients were compared.

The results showed that 29% of the patients had a change in pill shape or color during the study, correlating with a total of 4, 573 episodes of non-persistence. Statins had the most changes in appearance, whereas β-blockers had the fewest. The researchers found that the odds of nonpersistence in case patients increased by 34% after a change in pill color and 66% after a change in pill shape. Further adjusting the odds ratios for pharmacy changes or use of a mail-order pharmacy did not change the statistically significant associations with nonpersistence, except for color alone. The study was published on July 14, 2014, in Annals of Internal Medicine.

“Some pharmacies do alert patients to changes in medication appearance by placing a sticker on the container. But pill bottles can have so many stickers that the message might be missed,” said lead author Aaron Kesselheim, MD. “Patients need to know that it's common for generics to change their appearance, and that doesn't mean they're working any differently. If patients are concerned by a shift in their medication's shape or color, they should call their doctor or pharmacist rather than just abandoning the drug—even for a short time.”

Currently, the US Food and Drug Administration (FDA) do not interfere with the visual appearance of drugs, which are considered a form of intellectual property. However, the US Supreme Court ruled in 1995 that if the color of a medical pill served a specific function, then competitors were allowed to copy it.

Related Links:

Brigham and Women's Hospital



BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.